BioSpace News Archive

Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients’ lives, today announced that the Company will report financial results for the second quarter 2022 after market close on Monday, August 15, 2022.

Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the second quarter ended June 30, 2022.

Panbela Therapeutics, Inc., a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, announced that it will host a conference call on August 15, 2022, at 4:30 PM Eastern Time to discuss results for its second quarter ended June 30, 2022.

Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, reported second quarter 2022 financial results and business highlights.

Nautilus Biotechnology, Inc., a company pioneering a single-molecule protein analysis platform for quantifying the proteome, announced further expansion of its management team with the appointments of Eric Spence as Vice President of Instrument Engineering and Ken Kuhn, Ph.D., as Vice President of Reagent and Platform Development.

Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the discovery, development, and commercialization of drug therapies, novel vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the second quarter ended June 30, 2022, on Wednesday, August 10, 2022, following the close of market.

Amgen (NASDAQ:AMGN) today announced that it will report its second quarter financial results on Thursday, August 4, 2022, after the close of the U.S. financial markets.

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced it will report its second quarter 2022 financial results and operational highlights on Monday, August 8, 2022, following the close of U.S. financial markets.

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that the Company approved the grant of stock options to purchase an aggregate of 26,100 shares of Karyopharm’s common stock and an aggregate of 18,000 restricted stock units to eight newly-hired employees.

TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended June 30, 2022.